Cargando…

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current appro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Faith E., Pawlyn, Charlotte, Usmani, Saad Z., San-Miguel, Jesus F., Einsele, Hermann, Boyle, Eileen M., Corre, Jill, Auclair, Daniel, Cho, Hearn Jay, Lonial, Sagar, Sonneveld, Pieter, Stewart, A. Keith, Bergsagel, P. Leif, Kaiser, Martin F., Weisel, Katja, Keats, Jonathan J., Mikhael, Joseph R., Morgan, Kathryn E., Ghobrial, Irene M., Orlowski, Robert Z., Landgren, C. Ola, Gay, Francesca, Caers, Joseph, Chng, Wee Joo, Chari, Ajai, Walker, Brian A., Kumar, Shaji K., Costa, Luciano J., Anderson, Kenneth C., Morgan, Gareth J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894570/ https://www.ncbi.nlm.nih.gov/pubmed/35653112 http://dx.doi.org/10.1158/2643-3230.BCD-21-0205

Ejemplares similares

MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21(Cip1)
por: Mei, Anna Huo-Chang, et al.
Publicado: (2020)

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma
por: Stein, Caleb K., et al.
Publicado: (2017)

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life
por: Terpos, Evangelos, et al.
Publicado: (2021)

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
por: Shah, Nina, et al.
Publicado: (2020)

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
por: Miller, A, et al.
Publicado: (2017)

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
por: Perrot, Aurore, et al.
Publicado: (2021)

Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States
por: Auclair, Daniel, et al.
Publicado: (2022)

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2018)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Molecular profiling in myeloma
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
por: Chng, Wee-Joo, et al.
Publicado: (2023)

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL
por: Bahlis, Nizar J, et al.
Publicado: (2023)

Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
por: Bhalla, Sherry, et al.
Publicado: (2021)

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
por: Davies, Faith, et al.
Publicado: (2021)

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS
por: Weisel, K., et al.
Publicado: (2022)

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring
por: Chari, Ajai, et al.
Publicado: (2014)

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies
por: Lancman, Guido, et al.
Publicado: (2018)

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study
por: Mikhael, Joseph, et al.
Publicado: (2018)

Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
por: Ashby, Cody, et al.
Publicado: (2022)

Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022)

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
por: Walker, Brian A., et al.
Publicado: (2018)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
por: Lejeune, Margaux, et al.
Publicado: (2020)

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
por: Lonial, Sagar, et al.
Publicado: (2021)

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
por: Pawlyn, C, et al.
Publicado: (2017)

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2021)

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
por: Murray, David L., et al.
Publicado: (2021)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
por: Theodoropoulos, Nicholas, et al.
Publicado: (2020)

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
por: Bhutani, Manisha, et al.
Publicado: (2023)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
por: Usmani, S Z, et al.
Publicado: (2015)

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
por: Chari, Ajai, et al.
Publicado: (2020)

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
por: Jain, Tania, et al.
Publicado: (2017)

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
por: Popat, R, et al.
Publicado: (2022)

Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells
por: Suzuki, Erika, et al.
Publicado: (2011)

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution
por: Bonomo, Lauren, et al.
Publicado: (2016)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ucembji9mbfmel1p49pkiem1o4